The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
|Videos|January 22, 2019
Time Points in the Assessment of MRD
Advertisement
" width="560">Transcript:Mark R. Litzow, MD: Anthony, when do you think we should be measuring MRD?
Anthony S. Stein, MD: I think it also depends which regimen you
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5